Hyun Woo Ma
Overview
Explore the profile of Hyun Woo Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park Y, Ahn J, Kim D, Park I, Son M, Kim J, et al.
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928402
The gut microbial and metabolic characteristics of intestinal Behçet's disease (BD), a condition sharing many clinical similarities with ulcerative colitis (UC) and Crohn's disease (CD), are largely unexplored. This study...
2.
Ma H, Kim J, Kim D, Park I, Kim J, Park K, et al.
Cancer Gene Ther
. 2022 Dec;
30(5):694-703.
PMID: 36577836
Development of colorectal cancer (CRC) is regulated by a series of genetic and microenvironmental alterations. Olfactomedin 4 (OLFM4) is a secreted glycoprotein that is highly expressed in the gastrointestinal tract...
3.
Kim J, Yoo J, Ma H, Park I, Son M, Shin Y, et al.
Intest Res
. 2022 Nov;
21(2):266-269.
PMID: 36366930
No abstract available.
4.
Lee J, Ma H, Kim J, Park I, Son M, Ryu K, et al.
Gut Liver
. 2022 Sep;
17(5):766-776.
PMID: 36167345
Background/aims: The purpose of the current study was to examine the anti-inflammatory effects of CKD-506, a novel histone deacetylase 6 inhibitor, on human peripheral blood mononuclear cells (PBMCs) and CD4+...
5.
Son M, Park I, Kim S, Ma H, Kim J, Kim T, et al.
Front Immunol
. 2022 Jun;
13:870817.
PMID: 35693794
Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal...
6.
Park J, Kim D, Kim S, Ma H, Park I, Son M, et al.
Intest Res
. 2021 Nov;
19(4):478-481.
PMID: 34731563
No abstract available.
7.
Kim D, Park J, Kim S, Yoon M, Ma H, Park I, et al.
Free Radic Biol Med
. 2021 Aug;
174:110-120.
PMID: 34358646
Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract whose occurrence is attributed to various factors, including genetic factors, immune response, microbial changes, and oxidative...
8.
Seo D, Che X, Kim S, Kim D, Ma H, Kim J, et al.
Front Immunol
. 2021 Mar;
12:650864.
PMID: 33767714
Triggering receptor expressed on myeloid cell-1 (TREM-1) signaling is expressed on neutrophils and monocytes that is necessary for the successful antimicrobial response and resolution of inflammation in the gut. In...
9.
Park I, Son M, Ma H, Kim J, Kim D, Kim S, et al.
Intest Res
. 2020 Oct;
19(3):349-353.
PMID: 33120440
The safety and effectiveness of adalimumab was demonstrated in a phase 3 trial in Japanese patients with intestinal Behçet's disease. The aim of this study was to evaluate the long-term...
10.
Kim J, Kim D, Park H, Ma H, Park I, Son M, et al.
J Nanobiotechnology
. 2020 Sep;
18(1):133.
PMID: 32933548
Background: Infliximab (IFX), a TNF-α blocking chimeric monoclonal antibody, induces clinical response and mucosal healing in patients with inflammatory bowel disease (IBD). However, systemic administration of this agent causes unwanted...